Actively Recruiting
Glucagon Resistance in Patients With MASLD and T2DM
Led by University of Aarhus · Updated on 2026-02-04
24
Participants Needed
1
Research Sites
130 weeks
Total Duration
On this page
Sponsors
U
University of Aarhus
Lead Sponsor
N
Novo Nordisk A/S
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to investigate the sensitivity to glucagon in patients with type 2 diabetes mellitus (T2DM), with and without metabolic associated fatty liver disease (MASLD). The main questions it aims to answer are: 1. Is the sensitivity to glucagon with respect to hepatic FA oxidation and suppression of VLDL-TG secretion impaired in humans with T2DM and MASLD? 2. Is glucagon resistance and MASLD reflected in an aberrated lipidomic/metabolomic profile in blood and adipose tissue? Researchers will compare patients with T2DM with and without MASLD to see if the response to basal and high levels of glucagon differs between the groups. Participants will attend 2 short visits and 1 full-day visit, including: * Body scan (DXA) to check fat and bone composition * MRI to measure liver fat. * Blood tests. * Ultrasound to check liver stiffness and scarring. * Fat biopsies * 8-hour hormone (including glucagon) and tracer infusion * PET-CT scans
CONDITIONS
Official Title
Glucagon Resistance in Patients With MASLD and T2DM
Who Can Participate
Eligibility Criteria
You may qualify if you...
- BMI > 26 kg/m²
- Confirmed diagnosis of Type 2 Diabetes Mellitus for at least 6 months
- Steatosis fat fraction > 5.6% on MR spectroscopy for MASLD group
You will not qualify if you...
- Alcohol abuse (>10 units per week) or other substance abuse
- Smoking
- Current or previous malignant disease
- Blood donation within 3 months prior to study
- Participation in studies involving radioactive isotopes within 3 months
- Pregnancy
- Severely uncontrolled type 2 diabetes mellitus (haemoglobin A1c ≥ 100 mmol/mol)
- C-peptide < 200 pmol/L
- Previous acute myocardial infarction
- Clinical symptoms of heart failure
- Known ongoing systemic disease except dyslipidaemia and hypertension
- Regular use of medication affecting lipid and glucose metabolism including insulin treatment, except certain allowed medications with washout period or withheld on study day
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Aarhus University Hospital
Aarhus, Denmark, 8000
Actively Recruiting
Research Team
K
Kia E. Fonfara, Medical Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here